mAIbe joins ERYSO – Horizon Europe MSCA Staff Exchanges
mAIbe joins ERYSO
Horizon Europe MSCA Staff Exchanges
Photodynamic Therapy | Sonodynamic Therapy
Funded by the European Union
Horizon Europe MSCA
mAIbe is proud to announce its participation in ERYSO, a newly approved Horizon Europe – MSCA Staff Exchangesproject funded by the European Commission, which received an outstanding evaluation score.
ERYSO is a large, international research initiative bringing together 14 partners from Europe, the Middle East, Asia, Africa, and South America, including leading universities, research institutions, and innovative companies. The project focuses on the development of engineered erythrocytes and erythrocyte-derived extracellular vesicles as enabling platforms for advanced photodynamic and sonodynamic cancer therapies, with the goal of advancing personalized and multimodal treatment strategies.
Over the next four years, the ERYSO consortium will foster scientific exchange, interdisciplinary collaboration, and mobility between academic and industrial partners, addressing key technological and translational challenges at the interface of biomedical engineering, oncology, and advanced therapeutic modalities.
Within ERYSO, mAIbe contributes
its AI-driven and translational perspective, bridging computational design, data-driven modeling,
and biological validation.
Our participation reflects mAIbe’s broader mission to leverage artificial intelligence as a catalyst for accelerating biomedical innovation and transforming cutting-edge research into clinically meaningful solutions.
The project represents a concrete example of how academia and industry can work together at a global scale to address complex biomedical challenges and shorten the path from scientific discovery to patient impact.
mAIbe thanks the European Commission and all ERYSO partners for the trust placed in this collaboration and looks forward to contributing to the success of the project through scientific exchange, innovation, and shared expertise.